Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 in Patients Who Require Parenteral Nutrition
NCT ID: NCT06625957
Last Updated: 2025-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
60 participants
INTERVENTIONAL
2024-12-04
2025-07-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Trial to Evaluate the Safety and Efficacy of NTCB01-1 in Patients Who Require Parenteral Nutrition
NCT06625931
Continuous Versus Intermittent Enteral Feeding in Critically Ill Patients
NCT02159456
Home Enteral Nutrition in Malnourished Patients With Gastrointestinal Cancer
NCT02664974
A Study of an Oral Nutritional Supplement in a Malnourished Population With GI Tolerance Impairment
NCT02698540
Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Inj. Compared With RCN301
NCT05299099
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NTCB02-1
NTCB02-1
3 Days infusion
NTCB-C
NTCB-C
3 Days infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NTCB02-1
3 Days infusion
NTCB-C
3 Days infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients are expected to require PN for more than 3 days
* Patients who voluntarily signed the consent form
Exclusion Criteria
* Patients BMI is over 30 kg/m2
* Patients having hypersensitivity to any peanut-, fish-, soy-, egg protein, or investigational drug
* Patients with difficult central venous line
* Patients judged to be unsuitable for this trial by investigators
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yuhan Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Cancer Center
Gyeonggi-do, Goyang-si, South Korea
Chonnam National University Hwasun Hospital
Jeollanam-do, Hwasun-gun, South Korea
Jeonbuk National University Hospital
Jeollabuk-do, Jeonju-si, South Korea
Severance Hospital
Seoul, Seodaemun-gu, South Korea
Seoul National University Bundang
Gyeonggi-do, Seongnam-si, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NTCB02-301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.